New drug JAB-2485 targets Hard-to-Treat cancers in early trial

NCT ID NCT05490472

First seen Nov 12, 2025 · Last updated Jun 16, 2026 · Updated 29 times

Summary

This study tests a new drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 102 people will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100101, China

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Jilin Cancer Hospital

    RECRUITING

    Changchun, Jilin, 130000, China

  • Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75230, United States

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100101, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • University of Utah Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.